Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03522064 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Bipolar Androgen Therapy + Carboplatin in mCRPC

Study acronym: HiTeCH
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 23, 2026 (before its estimated September 30, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Sep 30, 2025 to Sep 30, 2026
    • Study completion date: Dec 30, 2025 to Dec 30, 2027
    v12
  2. Primary completion date: Dec 30, 2024 to Sep 30, 2025v11
  3. Primary completion date: Dec 30, 2022 to Dec 30, 2024
    • Study completion date: Dec 30, 2022 to Dec 30, 2025
    v10
  4. Re-verified, no change to tracked fieldsv9
  5. Study description shortened, about 45 words
    • Study arms: 2 to 1
    • Study title shortened, about 4 words
    v8
Show 6 earlier versionsHide 6 earlier versions
  1. Primary and study completion dates: Jul 30, 2021 to Dec 30, 2022
    • Secondary endpoints: 4 to 3
    v7
  2. Study title shortened, about 2 wordsv6
  3. Interventions: Testosterone Enanthate (Drug) to Testosterone Enanthate 100 MG/ML Injectable Solution / Carboplatin AUC 5 (Drug), Testosterone Enanthate 100 MG/ML Injectable Solution (Drug)
    • Study description expanded, about 20 words
    • Study arms: 1 to 2
    v5
  4. Primary completion date: Jul 30, 2020 to Jul 30, 2021v4
  5. Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less
    • Study sites: 0 to 1
    • Primary completion date: Mar 30, 2020 to Jul 30, 2020
    • Study completion date: Mar 30, 2021 to Jul 30, 2021
    • Start date changed from estimate of Jun 30, 2018 to Jul 30, 2018
  6. Start date: Apr 30, 2018 to Jun 30, 2018v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to determine the efficacy of BAT and carboplatin in men with metastatic castrate-resistant prostate cancer (mCRPC).
Trial Details
NCT Number NCT03522064
Lead Sponsor St Vincent's Hospital, Sydney
Conditions
(from sponsor)		 Castration-resistant Prostate Cancer, Homologous Recombination Deficiency
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov